



# Analytical Test Report

Science First. ORELAP ID: 4101 OLCC#: 010-10035537931

63055 Layton Ave., Bend, OR 97701 (541) 382-3796

## Full Spectrum Liposomal CBD 300mg

Lab ID: B230319-07

Jaxon Technologies

METRC Batch ID:

Date Sampled: 03/07/23

Date Printed: 03/30/23

This is an official amended report.  
Report cannot be used for OLCC/OHA compliance.



Original report printed 3/15/2023 - Report amended upon client's request to display results in adjusted units (% instead of mg/g)

## Potency Analysis

Analytical Method: JA-Potency\_proprietary  
SOP 102 - Potency Analysis by HPLC-UV-Vis

Cannabinoids	%	LOQ	Notes
THCA	< LOQ	0.0112	
delta 9-THC	< LOQ	0.0112	
delta 8-THC	< LOQ	0.0112	
CBDA	< LOQ	0.0112	
CBGA	< LOQ	0.0112	
CBD	1.43	0.0112	
CBG	0.0364	0.0112	
CBN	< LOQ	0.0112	
CBC	0.106	0.0112	
THCV	< LOQ	0.0112	
Total CBG	0.0364	0.0112	
Total Cannabinoids	1.57	0.0112	

**Total THC**  
**< LOQ %**

**Total CBD**  
**1.43 %**

<LOQ - Results below the Limit of Quantitation

Acid form of THC/CBD are decarboxylated by heat, lose 12% of original mass as CO<sub>2</sub>. Result = "bioactive"

"Total" Cannabinoid accounts for decarboxylation and moisture content. Total THC = [(THCA×0.877) + Δ9THC] / (100%-MC)

 **Zoe Wiggers**  
Technical Director

Sample tested in compliance with OAR 333-007 (TNI standards). Test results meet all requirements of NELAP and the Juniper Analytics quality assurance plan unless otherwise noted. Samplings performed by JA personnel follow sampling SOP JA\_100. Samples not collected by JA personnel are analyzed in "as received" condition. These results relate only to the sample included on this report. The report may not be reproduced except in full, without the written permission of Juniper Analytics LLC.



# Analytical Test Report

Science First. ORELAP ID: 4101 OLCC#: 010-10035537931

63055 Layton Ave., Bend, OR 97701 (541) 382-3796

## Full Spectrum Liposomal CBD 300mg

Jaxon Technologies

Laboratory ID: B230319-07

### Quality Control Potency

Batch: B23C051 - BB Potency

#### Blank(B23C051-BLK1)

Analyte	Result	LOQ	Units	%Recovery Limits	Extracted	Analyzed	Notes
THCA	< LOQ	0.0117	%		03/08/23 10:56	03/09/23 13:58	
delta 9-THC	< LOQ	0.0117	%		03/08/23 10:56	03/09/23 13:58	
CBGA	< LOQ	0.0117	%		03/08/23 10:56	03/09/23 13:58	
CBDA	< LOQ	0.0117	%		03/08/23 10:56	03/09/23 13:58	
CBD	< LOQ	0.0117	%		03/08/23 10:56	03/09/23 13:58	
CBN	< LOQ	0.0117	%		03/08/23 10:56	03/09/23 13:58	
CBG	< LOQ	0.0117	%		03/08/23 10:56	03/09/23 13:58	
delta 8-THC	< LOQ	0.0117	%		03/08/23 10:56	03/09/23 13:58	
CBC	< LOQ	0.0117	%		03/08/23 10:56	03/09/23 13:58	
Total CBG	< LOQ	0.0117	%		03/08/23 10:56	03/09/23 13:58	
THCV	< LOQ	0.0117	%		03/08/23 10:56	03/09/23 13:58	

#### LCS(B23C051-BS1)

Analyte	% Recovery	LOQ	Units	%Recovery Limits	Extracted	Analyzed	Notes
THCA	97.4	0.0546	%	90-110	03/08/23 10:56	03/09/23 13:58	
delta 9-THC	110	0.0546	%	90-110	03/08/23 10:56	03/09/23 13:58	
CBDA	96.9	0.0546	%	90-110	03/08/23 10:56	03/09/23 13:58	
CBD	102	0.0546	%	90-110	03/08/23 10:56	03/09/23 13:58	
delta 8-THC	100	0.0546	%	90-110	03/08/23 10:56	03/09/23 13:58	

 **Zoe Wiggers**  
Technical Director



# Analytical Test Report

Science First. ORELAP ID: 4101 OLCC#: 010-10035537931

63055 Layton Ave., Bend, OR 97701 (541) 382-3796

## Full Spectrum Liposomal CBD 300mg

*Jaxon Technologies*

Laboratory ID: B230319-07

### Notes and Definitions

- B Analyte detected in method blank, but not associated samples.
  - B2 Analyte detected in sample and associate method blank.
  - C Interference due to co-elution.
  - D Initial result exceeded calibration range, reported data are based on analysis of a dilution.
  - H Non-homogenous sample matrix affecting RPD and/or QC.
  - I Manual Integration was performed.
  - L Duplicate sample relative percent difference (RPD) exceeds QC limits.
  - M Anomalous results due to matrix interference
  - P Peaks manually split.
  - Q1 QC out of limits but still ok
  - Q2 Quality Control outside QC limits. Data considered estimate.
  - Q3 CCV was above the acceptance criteria. Non-detect samples are considered acceptable.
  - Q4 CCV was below the acceptance criteria, however the sample still exceeds the regulatory limit.
  - R Marginal Exceedence.
  - U Reported result is an estimate. The analyte was detected above the calibration range.
  - X Problems with initial analysis, reported data are from reinjection of prepared sample.
- <LOQ - Results below the Limit of Quantitation - Compound not detected

**Zoe Wiggers**  
Technical Director